Bristol Myers' 利益（をあげる） （警官の）巡回区域，受持ち区域s on better-than-恐れるd Revlimid sales
By Michael Erman
Feb 2 (Reuters) - Bristol Myers Squibb Co on Thursday 報告（する）／憶測d 年４回の 収入s that （警官の）巡回区域，受持ち区域 分析家s' 見積（る）s 予定 to a smaller-than-推定する／予想するd 減少（する） in sales of 癌 麻薬 Revlimid, which is 直面するing 競争 from cheaper generic 競争相手s.
Fourth-４半期/4分の1 Revlimid sales of $2.26 billion topped 塀で囲む Street 見積（る）s of $1.89 billion, によれば Refinitiv data.
The company 推定する／予想するs Revlimid sales to 落ちる to $6.5 billion in 2023 from $9.98 billion last year.
The 予測（する） 示唆するs Revlimid's "generic 腐食 will 加速する," William Blair 分析家s said in a 公式文書，認める.
To help 相殺する the 拒絶する／低下する in Revlimid sales, Bristol Myers has been betting on newer 製品s, such as 癌 therapies Opdualag and Abecma.
With the 勢い of the new 製品 大臣の地位, the company 推定する／予想するs to 概略で 二塁打 sales of its more 最近の offerings in 2023 versus last year to about $4 billion, 長，指導者 財政上の Officer David Elkins said on a call to discuss the company's results.
The New York-based drugmaker 報告（する）／憶測d a nearly 5% 拒絶する／低下する in sales in the fourth ４半期/4分の1 to $11.41 billion, but that was above 分析家s' 期待s of $11.2 billion.
除外するing the 影響 of foreign 交流, sales grew 3% in 2022, the CFO said.
"This is the first year of generic (競争 for Revlimid) and everybody 手配中の，お尋ね者 to see if we could grow through the year. We did that," Elkins said.
Bristol Myers 株 were up about 1% at $72.06.
The company 報告（する）／憶測d sales of $2.69 billion for the 血 thinner Eliquis that it 株 with Pfizer Inc in the ４半期/4分の1, and $2.22 billion for 癌 immunotherapy Op divo, up 1% and 11% over a year earlier, それぞれ.
Bristol Myers said it earned $1.82 per 株 in the ４半期/4分の1, 負かす／撃墜する from $1.84 a year ago. 分析家s, on 普通の／平均（する）, had 推定する／予想するd 収入s of $1.72 per 株.
The company 予測（する） 2023 収入s of $7.95 to $8.25 a 株, on 歳入 it sees 増加するing by about 2% from 2022 sales of $46.16 billion. (報告（する）／憶測ing by Michael Erman in New Jersey and Raghav Mahobe in Bengaluru; Editing by Bradley Perrett and 法案 Berkrot)
